Ovid Therapeutics Inc (OVID)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $479.38M
Last updated: Nov 17, 2026 at 11:06 AM ET
Ovid Therapeutics Inc (OVID) Competitors
The companies most similar to Ovid Therapeutics are Oculis Holding AG Ordinary shares (OCS), Oric Pharmaceuticals (ORIC) and Ocugen (OCGN). By market cap, Ovid Therapeutics ranks 7th of the 13 companies on this page; Oric Pharmaceuticals (ORIC) is the largest at $814.71M.
Peer Comparison
OVID's revenue growth of -88.3% is below the peer median of 0.0%. Like the median peer, it pays no dividend.
| Company | Market cap | P/E | P/S | Net margin | ROIC | Rev growth | Div yield |
|---|---|---|---|---|---|---|---|
| Ovid Therapeutics (OVID) | $479.38M | N/A | 335.8x | 0.0% | N/A | -88.3% | 0.00% |
| Oculis Holding AG Ordinary shares (OCS) | $425.67M | N/A | N/A | 0.0% | N/A | -97.1% | 0.00% |
| Oric Pharmaceuticals Inc (ORIC) | $814.71M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Ocugen Inc (OCGN) | $280.88M | N/A | 54.9x | 0.0% | 271.0% | 11.4% | 0.00% |
| Olema Pharmaceuticals Inc (OLMA) | $662.30M | N/A | N/A | 0.0% | -53.8% | 0.0% | 0.00% |
| Opus Genetics, Inc. (IRD) | $384.68M | N/A | 52.0x | 0.0% | -145.1% | -63.1% | 0.00% |
| Tevogen Bio Holdings Inc. (TVGN) | $406.59M | N/A | N/A | 0.0% | 2022.8% | 0.0% | 0.00% |
| Zevra Therapeutics Inc. (ZVRA) | $540.30M | 11.6x | 3.7x | 52.8% | N/A | 44.9% | 0.00% |
| Alector Inc (ALEC) | $378.15M | 7.3x | 1.7x | 23.9% | N/A | 4896.0% | 0.00% |
| Nuvectis Pharma Inc (NVCT) | $696.03M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Avalo Therapeutics Inc (AVTX) | $448.71M | N/A | N/A | 0.0% | N/A | -69.3% | 0.00% |
| Neurogene Inc (NGNE) | $495.37M | N/A | N/A | 0.0% | -28.5% | 0.0% | 0.00% |
| Immix Biopharma Inc (IMMX) | $657.09M | N/A | N/A | 0.0% | -14.9% | 0.0% | 0.00% |
| Peer median | $472.04M | 9.5x | 27.9x | 0.0% | -21.7% | 0.0% | 0.00% |
Similar Companies
These are the 12 companies most similar to Ovid Therapeutics, ranked by how closely their business, size, sector and industry match. All 12 are in one industry, Biotechnology.
| Company | About | Peers |
|---|---|---|
| Oculis Holding AG Ordinary shares (OCS) | Oculis Holding AG, a biopharmaceutical company, develops novel topical treatments for ophthalmic diseases for both back- and front-of-the-eye. | OCS competitors |
| Oric Pharmaceuticals Inc (ORIC) | ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for the treatment of cancers. | ORIC competitors |
| Ocugen Inc (OCGN) | Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on the development of gene therapies to cure diseases of blindness. | OCGN competitors |
| Olema Pharmaceuticals Inc (OLMA) | Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development... | OLMA competitors |
| Opus Genetics, Inc. (IRD) | Opus Genetics, Inc. (IRD) is a pioneering biotechnology company dedicated to advancing gene therapies for rare retinal diseases that affect vision. | IRD competitors |
| Tevogen Bio Holdings Inc. (TVGN) | Tevogen Bio Holdings Inc. is a clinical-stage biotechnology company that develops off-the-shelf precision T cell therapeutics in virology, oncology... | TVGN competitors |
| Zevra Therapeutics Inc. (ZVRA) | Zevra Therapeutics, Inc., a rare disease company melding science, discovers and develops various proprietary prodrugs to treat serious medical conditions... | ZVRA competitors |
| Alector Inc (ALEC) | Alector, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of neurodegenerative diseases. | ALEC competitors |
| Nuvectis Pharma Inc (NVCT) | Nuvectis Pharma, Inc., a biopharmaceutical company, is focused on the development of targeted small molecule therapies for the treatment of cancer. | NVCT competitors |
| Avalo Therapeutics Inc (AVTX) | Avalo Therapeutics Inc is a forward-thinking clinical-stage biotechnology company focused on developing transformative therapies for rare and underserved... | AVTX competitors |
| Neurogene Inc (NGNE) | Neurogene Inc. is an innovative biotechnology company at the forefront of developing advanced gene therapies for rare neurological disorders... | NGNE competitors |
| Immix Biopharma Inc (IMMX) | Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, is dedicated to the development of various tissue-specific therapies in oncology... | IMMX competitors |
Frequently Asked Questions About OVID
Who are Ovid Therapeutics' main competitors?
The companies most similar to Ovid Therapeutics include Oculis Holding AG Ordinary shares (OCS), Oric Pharmaceuticals (ORIC), Ocugen (OCGN), Olema Pharmaceuticals (OLMA) and Opus Genetics (IRD), listed from the closest match.
Who is Ovid Therapeutics' biggest competitor?
Oric Pharmaceuticals (ORIC) is the largest of the similar companies at $814.71M; Oculis Holding AG Ordinary shares (OCS) is the closest match by business profile, size, sector and industry.
How does OVID stock compare with its competitors?
OVID's P/S is 335.8x against a peer median of 27.9x; its net margin is 0.0% against a peer median of 0.0%.
Which of Ovid Therapeutics' competitors pays a higher dividend?
Ovid Therapeutics pays no dividend. None of the similar companies with available yields has a higher forward dividend yield.
Is Ovid Therapeutics bigger than its competitors?
No. Ovid Therapeutics is 7th by market cap among the 13 companies on this page; the largest is Oric Pharmaceuticals (ORIC) at $814.71M.
OVID pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors